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Purpose: Clinical study has previously revealed that plasma concentration of 
7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan, was 
higher in patients with end-stage renal failure than those with normal kidney function 
although SN-38 is mainly eliminated in the liver. Here, we focused on inhibition by 
uremic toxins of hepatic SN-38 uptake and down-regulation of uptake transporter(s) by 
uremic plasma in humans. 
Methods: We evaluated SN-38 uptake and its inhibition by uremic toxins, 
3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF), indoxyl sulfate (Indox), 
hippuric acid (HA) and indole acetate (IA), with cryopreserved human hepatocytes and 
HEK293 cells stably expressing hepatic uptake transporters, organic anion transporting 
polypeptides (OATPs). We also collected plasma samples from patients with severe 
renal failure to examine their effects on mRNA level of OATPs in primary cultured 
human hepatocytes. 
Results: SN-38 was taken up by hepatocytes, which showed biphasic saturation 
patterns. The SN-38 uptake by hepatocytes was significantly inhibited by a uremic toxin 
mixture including clinically relevant concentrations of CMPF, Indox, HA and IA. 
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Kinetic analyses for OATP-mediated transport revealed that the uptake of SN-38 by 
OATP1B1 was the highest, followed by OATP1B3. Among the uremic toxins, CMPF 
exhibited most potent inhibition of OATP1B1-mediated SN-38 uptake and directly 
inhibited the uptake of SN-38 also in hepatocytes. In addition, gene expression of 
OATP1B1 and OATP1B3 in hepatocytes was significantly down-regulated by the 
treatment with the uremic plasma. 
Conclusions: OATP1B1-mediated hepatic uptake of SN-38 was inhibited by uremic 
toxins, and gene expression of OATP1B1 was down-regulated by uremic plasma. 
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ABCB1, ATP-binding cassette, sub-family B, member 1; BCRP, breast cancer 
resistance protein; CMPF, 3-carboxy-4-methyl-5-propyl-2-furanpropionate; CLcr, 
creatinine clearance; E217βG,  estradiol 17-β-D-glucuronide; eGFR, estimated 
glomerular filtration rate; HA, hippuric acid; HPLC, high-performance liquid 
chromatography; IA, indole acetate; Indox, indoxyl sulfate; MRP2, multidrug 
resistance-associated protein 2; OAT, organic anion transporter; OATP, organic anion 
transporting polypeptide; RIF, rifampicin; RT-PCR, real-time polymerase chain 
reaction; SEM, standard error of mean; SN-38, 7-ethyl-10-hydroxycamptothecin; UGT, 
UDP-glucuronosyltransferase (UGT);  
 
INTRODUCTION 
Irinotecan hydrochloride has been widely used in cancer chemotherapy. 
7-Ethyl-10-hydroxycamptothecin (SN-38) is an active metabolite of irinotecan that is 
extensively produced in the liver by carboxylesterase. It is subsequently detoxified, 
predominantly by UDP-glucuronosyltransferase (UGT) 1A1 in the liver, to form SN-38 
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glucuronide (chemical structures; http://www.pharmgkb.org/views/pathway/PA2001- 
metablites.html). Transporters expressed in the liver are implicated in various aspects of 
SN-38 pharmacokinetics. A primary active transport system is involved in permeation 
of SN-38 across canalicular membranes in both humans and rats, and multidrug 
resistance-associated protein 2 (MRP2) and breast cancer resistance protein (BCRP) 
mediate its biliary excretion (1-3) (http://www.pharmgkb.org/do/serve?objId=PA2001 
&objCls=Pathway). A part of SN-38 produced in the liver is considered to be 
transported to systemic circulation across sinusoidal membranes by the unidentified 
transporter(s) because of the fact that SN-38 is detectable in plasma immediately after 
the irinotecan injection in patients with cancer. SN-38 is a substrate of organic anion 
transporting polypeptides (OATPs), which are localized on sinusoidal membranes in 
humans (4, 5), and playing roles in the uptake of a variety of therapeutic drugs into 
hepatocytes, although their contribution to overall hepatic uptake of SN-38 has not yet 
been established. 
We previously reported that the plasma concentration profile of SN-38, but 
not irinotecan or SN-38 glucuronide, was significantly delayed in patients with severe 
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renal failure who underwent hemodialysis, as compared with that in patients without 
renal failure (terminal elimination rate constant, 0.0084 ± 0.0037 vs. 0.081 ± 0.034 h-1 
[mean ± standard deviation]) (6), even though SN-38 is mainly eliminated by the liver 
via glucuronidation and biliary excretion. Mean area under the concentration-time curve 
of SN-38 calculated from time zero to 24 h in the patients with severe renal failure was 
1.6-fold greater than that in the patients without renal failure (1.3 ± 0.7 vs. 0.83 ± 0.55 
µM·h) (6). The mechanism(s) underlying the delayed elimination of SN-38 in these 
patients remains unclear. It should be noted that all the patients with severe renal failure 
suffered from grade 2 to 4 neutropenia, even though dialyses were performed (6). The 
prolonged neutropenia seen in these patients resulted in delay of the second irinotecan 
treatment (6). Since SN-38 concentrations has been reported to be still remained 
detectable even at 500 hr after drug administration in patients with normal renal 
function (7), it could be postulated that the long period of exposure to relatively high 
concentration of SN-38 was one of causes of the prolonged neutropenia in these cancer 
patients with severe renal failure. Thus, it is important to clarify the mechanism(s) of 
delayed elimination of SN-38 in order to establish an appropriate irinotecan 
7 
 
chemotherapy protocol for renal failure patients, without increased risk of severe 
adverse reactions. 
Several lines of evidence have recently suggested that renal failure 
differentially affects drug uptake/efflux transporters and drug-metabolizing enzymes in 
the liver. Therefore, even drugs that are predominantly eliminated by hepatic transport 
and/or metabolism can be affected by severe renal failure, leading to unexpected 
consequences, such as atypical pharmacokinetics and an increased risk of adverse drug 
reactions. High levels of uremic toxins in such patients are at least partially implicated 
in these effects of renal failure (8). Indeed, in our previous study, plasma concentrations 
of organic anionic uremic toxins, such as 
3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF), indoxyl sulfate (Indox), 
indole acetate (IA) and hippuric acid (HA), increased in parallel with the degree of renal 
impairment (6). These four uremic toxins were selected for study since they are organic 
anions that might interact with organic anion transporters in the liver, and there is a 
sufficient body of literature on their properties (6). It has been reported that CMPF and 
Indox directly inhibit OATP1B1-mediated uptake of a typical substrate, 
8 
 
estrone-3-sulfate (E3S), in a mammalian cell line exogenously transfected with 
OATP1B1 cDNA (9). We hypothesized that the elevation of SN-38 plasma 
concentration in patients with severe renal failure was caused by the inhibition of 
hepatic uptake of SN-38 by uremic toxins. So far, information on the characteristics of 
inhibition of hepatic uptake transporters by uremic toxins is still quite limited (9). In 
addition, there has been no report directly concerning the interaction of uremic toxins 
with hepatic transporters responsible for SN-38 uptake in human hepatocytes. Another 
hypothesis was that reduced gene expression of uptake transporters in patients with 
severe renal failure (8). 
Therefore, in the present study, we set out to examine the inhibition of SN-38 
uptake in human liver by organic anionic uremic toxins mentioned above. To clarify the 
interaction of the SN-38 with hepatic uptake transporters, cryopreserved human 
hepatocytes and HEK293 cells stably expressing human OATPs were used. We further 
investigated the inhibition of SN-38 uptake by the uremic toxins in the human 
hepatocytes and the HEK293 cells in order to estimate direct effects of the toxins in 
humans. Additionally, to clarify the possible long-term effects of uremic plasma on 
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hepatic uptake transporters in humans, we examined effects of human plasma obtained 
from patients with severe renal failure (uremic plasma) on gene expression of OATPs in 
cultured human hepatocytes.  
 
MATERIALS AND METHODS 
Materials.  
[3H]E3S (57.3 Ci/mmol) and [14C]inulin (2.8 mCi/g) were purchased from 
PerkinElmer Life and Analytical Sciences (Waltham, MA). [3H]Estradiol 
17β-glucuronide ([3H]E217βG) (41.8 Ci/mmol) was obtained from American 
Radiolabeled Chemicals (St. Louis, MO). Camptothecin, IA, HA and rifampicin (RIF) 
were obtained from Wako Pure Chemical (Osaka, Japan), and SN-38 and Indox from 
Sigma-Aldrich Japan (Tokyo, Japan). SN-38 was first dissolved in 50 mM phosphate 
buffer at pH 9.0 and kept overnight to convert the compound to its carboxylate form 
(>99%) (2). CMPF was purchased from Cayman Chemical Company (Ann Arbor, MI). 
Cryopreserved human hepatocytes (H1000.H15T, Lot#694, 29-year-old male Caucasian 
and H1500.H15T, Lot#706, 53-year-old female Caucasian; [XenoTech, Lenexa, KS]) 
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were obtained from Sekisui Medical (Tokyo, Japan). Plateable cryopreserved human 
hepatocytes (Cat#454541, Lot#276, 59-year-old female Hispanic; and Cat#HMCPUS, 
Lot#Hu1314, 25-year-old female Caucasian) were purchased from BD Biosciences (San 
Jose, CA) and Life Technologies (Carlsbad, CA), respectively. All other chemicals and 
reagents were of analytical grade and obtained from commercial sources. 
Transport Studies in HEK293 Cells Stably Transfected with OATP1B1, OATP1B3 
or OATP2B1. 
 HEK293 cells were transfected with pcDNA3 constructs containing full-length 
OATP1B1, OATP1B3 or OATP2B1 according to the calcium phosphate precipitation 
method. Cells were then selected by adding G418 (1 mg/mL, Wako Pure Chemical) to 
the culture medium to obtain HEK293/OATP1B1, HEK293/OATP1B3 and 
HEK293/OATP2B1 cells. These cells were routinely grown in D-MEM without 
L-glutamine and phenol red (Wako Pure Chemical) containing 10% fetal bovine serum, 
penicillin, streptomycin and 1 mg/mL G418 in a humidified incubator at 37°C and 5% 
CO2. After the cells had reached confluence, they were harvested and suspended in the 
transport buffer containing 125 mM NaCl, 4.8 mM KCl, 5.6 mM D-glucose, 1.2 mM 
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CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, and 25 mM HEPES (adjusted to pH 7.4 with 
1 N NaOH). The cell suspension and the transport buffer containing SN-38 or [3H]E3S 
were mixed to initiate the transport reaction. At the designated times, the mixture was 
diluted 6-fold with ice-cold transport buffer and then centrifuged for 1 min, and the 
supernatant was removed. The cells were washed three times with ice-cold buffer, and 
then disrupted in distilled water with a sonicator. The concentrations of SN-38 in the 
supernatant and cell lysates were measured by high-performance liquid chromatography 
(HPLC) as described below. [3H]E3S was measured as radioactivity using Clearsol I 
(Nacalai Tesque, Kyoto, Japan) as the scintillation fluid. The radioactivity was 
determined using a liquid scintillation counter (LSC-5100; Aloka, Tokyo, Japan). 
Transport Studies Using Cryopreserved Human Hepatocytes. 
Cryopreserved human hepatocytes were thawed and purified using a 
hepatocyte isolation kit (K2000, XenoTech) according to the manufacturer’s instruction. 
The cells were resuspended in the transport buffer (pH 7.4) to give a final concentration 
of 2 mg protein/mL. The number of viable cells was determined by trypan blue staining. 
The uptake experiment was then performed according to the silicone oil layer method 
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(10) with some modifications. In brief, 20 µL of the cell suspension was preincubated 
for 5 min at 37˚C, then the reaction was started by mixing the suspension with 80 µL of 
prewarmed transport buffer containing SN-38 with or without inhibitors. The reaction 
was stopped by addition of 600 µL of ice-cold transport buffer, and the mixture was 
then quickly centrifuged through a silicone oil layer (density, 1.015) to separate the cells 
from the medium. This dilution process was also expected to reduce the amount of 
cell-associated SN-38 in adhering water. Hepatocytes were then lysed overnight with 
alkali (3 N KOH), and the lysed hepatocytes and medium were stored at -20~-30˚C until 
HPLC analysis. The hepatocellular protein content was determined according to the 
method of Bradford using a protein assay kit (Bio-Rad Laboratories, Hercules, CA) 
with bovine serum albumin as the standard. The amounts taken up by the hepatocytes 
were expressed as the intracellular distribution volume (intracellular content divided by 
the SN-38 concentration in the medium) and corrected for the adherent water volume 
(1.94 μL/mg protein) which was determined as apparent distribution volume of 
extracellular marker [14C]inulin. 
Measurement of SN-38 by HPLC. 
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Total (lactone and carboxylate) concentration of SN-38 was analyzed by a 
modified reverse-phase HPLC method (11). A 40-µL sample was mixed with 60 µL of 
methanol, 10% perchloric acid (50:50, v/v) and 10 µL of camptothecin (internal 
standard) in a vortex mixer. The mixture was centrifuged at 15,000 rpm for 10 min, and 
the supernatant was injected into an HPLC system (Shimadzu LC-10Avp series; 
Shimadzu, Kyoto, Japan), equipped with a TSK-gel ODS-120T analytical column (4.6 
× 250 mm, 4 µm; TOSOH, Tokyo, Japan). HPLC was carried out at 40°C at a flow rate 
of 1.0 mL/min. SN-38 was determined fluorometrically (excitation 355 nm; emission 
515 nm). The mobile phase consisted of 75 mM ammonium acetate (pH 
4.75)/acetonitrile (86:14) for solvent A, and 75 mM ammonium acetate (pH 
4.75)/acetonitrile (60:40) for solvent B; a 25-min run was carried out with a linear 
gradient of 100-0 % solvent A.  
Kinetic Analyses.  
Kinetic parameters for transport activity were estimated by nonlinear 




V = Vmax • S/(Km + S)      (1) 
V = Vmax • S/(Km + S) + Pdif • S    (2) 
V = Vmax,1 • S/(Km,1 + S) + Vmax,2 • S/(Km,2 + S)   (3) 
where V, S, Km, Vmax and Pdif represent the initial uptake velocity, substrate 
concentration, Michaelis constant, maximum uptake velocity and clearance for 
non-saturable uptake, respectively. The selection of equation was based on the goodness 
of fit, considering Akaike’s information criteria. Concentration-dependent inhibition of 
the uptake by an inhibitor was fitted to the following equation:  
R = IC50
n/(IC50
 n + I n)      (4) 
where R, I, IC50 and n are the uptake normalized by the control (without inhibitor) value, 
the inhibitor concentration, the concentration for half-maximal inhibition, and Hill’s 
coefficient, respectively. 
Human Plasma Samples. 
Plasma samples were obtained from patients with normal renal function 
(estimated glomerular filtration rate (eGFR) of equal to or higher than 60 mL/min) or 
those with severe renal failure (<15 mL/min eGFR) (uremic plasma). All patients 
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enrolled did not receive dialysis, signed a written informed consent form, granting 
permission for their peripheral blood samples and medical information to be used for 
research purposes. The study protocol was approved by the Institutional Review Board 
of Saitama Medical University. 
Culture of Plateable Cryopreserved Human Hepatocytes. 
Plateable cryopreserved human hepatocytes were thawed and purified using a 
hepatocyte isolation kit (BD Gentest High Viability CryoHepatocyte Recovery kit, BD 
Biosciences) with 10% fetal calf serum according to the manufacturer’s instruction. Cell 
suspensions with viability rates of >95％ as assessed by trypan blue dye exclusion were 
used for the experiments. Hepatocytes were plated on BD BioCoat collagen I-coated 
plates (BD Biosciences). Seeding density was 40,000 cells per well of 24-well plate. 
Williams’ E medium supplemented with BD ITS Universal Culture Supplements, 4 mM 
L-glutamine, 0.1 µM dexamethasone and 100 U/mL penicilline-streptomycin was used 
as culture medium. After an incubation period of 4 hr at 37˚C, 5% CO2, and 95% 
humidity, nonattached cells were removed, and culture medium without serum was 
supplied. Twenty four hr after plating, medium was removed, and hepatocytes were 
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overlaid with 0.5 mL per well of culture medium containing 0.25 mg/mL BD Matrigel 
Matrix (BD Biosciences) and incubated for 24 hr at 37˚C, 5% CO2, and 95% humidity 
to obtain the sandwich cultures. Hepatocytes were then incubated for 48 hr with 10% 
human plasma obtained from patients with normal renal function (normal plasma) or 
uremic plasma diluted with culture medium. Hepatocytes were harvested by scraping in 
QIAzol® Lysis Reagent (Qiagen, Mississauga, ON) for mRNA analysis.  
Determination of mRNA by Real-time Polymerase Chain Reaction (RT-PCR). 
 Total RNA was extracted by the miRNeasy Mini Kit (Qiagen), and cDNA was 
synthesized using oligo (dT)12-18 primer, deoxynucleotide triphosphate mix, RT buffer 
and MultiScribe™ Reverse Transcriptase (Applied Biosystems, Foster City, CA). 
Quantification of mRNA for OATP1B1, OATP1B3 and ATP-binding cassette, 
sub-family B, member 1 (ABCB1) was performed using Mx3005P (Agilent 
Technologies, Santa Clara, CA). The sequences of the primers were as follows: 
OATP1B1 forward, GTT GCC GGA CTA ACC ATG AC and reverse, TCC ACA GAC 
TGG TTC CCA TT; OATP1B3 forward, CGG CCT AAC CTT GAC CTA TG and 
reverse, CAC AGA CTG GTT CCC ACT GA; ABCB1 forward, GCC CTT GTT AGA 
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CAG CCT CA and reverse, CCT TCT CTG GCT TTG TCC AG; 36B4 forward, GAA 
GTG CTT GAT ATC ACA GAG GAA and reverse, TGA TGC AAC AGT TGG GTA 
GC. The PCR conditions were as follows: initial denaturation at 95˚C for 15 min, 
followed by 40 cycles of denaturation at 95˚C for 10 sec (followed by an immediate 
change to the next temperature) and combined annealing extension at 60˚C for 30 sec. 
Statistical Analyses. 
Statistical analyses were performed by using Student’s t test. A difference 




Hepatic Uptake of SN-38. 
SN-38 is mainly eliminated by the liver through glucuronidation and biliary 
excretion, but no information is available on the characteristics of SN-38 uptake by 
human hepatocytes. Therefore, we directly examined hepatic SN-38 uptake using 
cryopreserved human hepatocytes. Both SN-38 and [3H]E3S were taken up by human 
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hepatocytes in a time-dependent manner (Fig. 1A, 1B). In both cases, uptake was higher 
in hepatocytes of Lot#706 than in those of Lot#694 (Fig. 1A, 1B). Kinetic analyses 
were then performed for SN-38 uptake by Lot#706 and Lot#694, which showed 
biphasic saturation patterns (Fig. 1C, 1D). The value of Akaike’s information criteria 
obtained by fitting of the data shown in Fig. 1C to Eqs. (1), (2) and (3) (-13.3, -24.0 and 
-22.7, respectively) was the lowest for Eq. (2), which yielded Km, Vmax and Pdif values 
of 9.29 µM, 63.5 pmol/min/mg protein and 3.77 µL/min/mg protein, respectively. Thus, 
the saturable portion of the uptake accounts for 60-70% of the overall uptake in 
Lot#706 hepatocytes. The value of Akaike’s information criteria for the data in Fig. 1D 
to three equations was the lowest for Eq. (3) (-23.0). Km,1, Vmax,1, Km,2 and Vmax,2 were 
0.22 µM, 0.78 pmol/min/mg protein, 40.9 µM and 334 pmol/min/mg protein, 
respectively. 
Inhibition by Uremic Toxin Mixtures of Hepatic SN-38 Uptake. 
Next, we examined the effects of the uremic toxins, CMPF, Indox, HA and IA, 
on the hepatic uptake of SN-38 in order to elucidate whether clinically relevant 
concentrations of these toxins inhibit the SN-38 uptake, which could be associated with 
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the increased plasma SN-38 concentration in patients with severe renal failure (6). Mix1 
consisted of a mixture of the toxins at the concentrations reported in our patients (6), 
while Mix2 was a mixture of the toxins at the highest concentrations previously 
reported in patients (13). When the human hepatocytes were incubated with SN-38 and 
the Mix1 (100 µM CMPF, 100 µM Indox, 100 µM HA and 10 µM IA), SN-38 uptake in 
Lot#706 was significantly reduced (Fig. 2A). The SN-38 uptake in Lot#694 tended to 
be inhibited by the addition of Mix1 to the similar extent to Lot#706 (Fig. 2B). When 
the hepatocytes were incubated with the Mix2 (300 µM CMPF, 1,000 µM Indox, 3,000 
µM HA and 100 µM IA), the SN-38 uptake was significantly reduced to the same extent 
as 100 µM RIF (Fig. 2A, 2B). 
Contribution of OATPs in the Hepatic Uptake of SN-38. 
 We estimated the contribution of OATP1B1 and another OATP uptake 
transporter, OATP1B3, to hepatic uptake of SN-38 in humans, since SN-38 has been 
reported to be a substrate of these OATP uptake transporters (4, 5). For this purpose, we 
added OATP inhibitors, E3S (10 µM), RIF (100 µM) or E3S (10 µM) plus RIF (100 
µM), to incubation mixture of human hepatocytes, since E3S can inhibit OATP1B1, but 
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RIF can inhibit both OATP1B1 and OATP1B3 when appropriate concentrations of E3S 
and RIF are used (9, 14). Uptake of SN-38 in Lot#706 of human hepatocytes was 
significantly inhibited by 10 µM E3S or 100 µM RIF (Fig. 2A). Inhibition of the hepatic 
uptake of SN-38 by E3S was tended to be less potent than that by RIF or a mixture of 
E3S and RIF (Fig. 2A). If E3S and RIF equally inhibit the SN-38 uptake, the uptake 
could be mainly mediated by OATP1B1, whereas, if E3S does not inhibit the SN-38 
uptake but RIF does, the uptake could be predominantly mediated by OATP1B3. The 
present results thus indicate the greater contribution of OATP1B1 to the hepatic uptake 
of SN-38 than OATP1B3. Significant inhibition of the SN-38 uptake by E3S, RIF or the 
mixture was also observed in human hepatocytes of Lot#694 (Fig. 2B). [3H]E3S is 
known to be taken up into human hepatocytes by OATPs (15). As shown in figure 2C, 
the uptake of [3H]E3S by human hepatocytes was sufficiently inhibited by E3S, RIF and 
the mixture of E3S and RIF.  
Characterization of OATP1B1-, OATP1B3- or OATP2B1-mediated Uptake of 
SN-38.   
Next, we characterized the OATP1B1-, OATP1B3- or OATP2B1-mediated 
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transport of SN-38. The uptake of SN-38 by HEK293/OATP1B1 and HEK/OATP1B3 
cells increased in a time-dependent manner and was higher than that in HEK293/mock 
cells (Fig. 3A, 3B), whereas the uptake by HEK293/OATP2B1 cells was almost 
comparable with that in HEK293/mock cells (Fig. 3C). OATP1B1- or 
OATP1B3-mediated uptake, which was obtained by subtracting the uptake in 
HEK293/mock cells from that in HEK293/OATP1B1 or HEK293/OATP1B3 cells, 
respectively, linearly increased up to 80 min (Fig. 3A, 3B). In positive control studies, 
OATP1B1-, OATP1B3-, and OATP2B1-mediated uptake of typical substrates were 
measured. OATP1B1-mediated [3H]E3S uptake, OATP1B3-mediated [3H]E217βG 
uptake, and OATP2B1-mediated [3H]E3S uptake were 113 ± 4 µL/mg protein/3 min, 
17.5 ± 2.9 µL/mg protein/10 min, and 207 ± 4 µL/mg protein/5 min, respectively. 
Kinetic analyses of the initial phase of OATP1B1- and OATP1B3-mediated SN-38 
uptake were performed. Clearance (V/S) for the OATP1B1-mediated SN-38 uptake was 
much higher than that for OATP1B3-mediated uptake (Fig. 3D, 3E), and this was 
consistent with higher value for the time course of OATP1B1-mediated uptake as 
compared with OATP1B3-mediated one (Fig. 3A, 3B). The data of OATP1B1-mediated 
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SN-38 uptake (Fig. 3D) was well fitted to Eq. (1) with the Km and Vmax of 4.97 µM 
and 1.71 pmol/min/mg protein, respectively. The SN-38 uptake by OATP1B3 (Fig. 3E) 
was well fitted to Eq. (3) with Km,1 and Km,2 of 0.0177 and 23.2 µM, respectively and 
Vmax,1 and Vmax,2 of 0.00371 and 0.561 pmol/min/mg protein, respectively.  
We further characterized the uptake of SN-38 by OATP1B1 and OATP1B3 
with the use of OATP inhibitors, E3S and RIF. OATP1B1-mediated uptake of SN-38 
was almost completely blocked in the presence of E3S (10-30 µM) and RIF (30-100 
µM) (Fig. 4A). OATP1B3-mediated uptake of SN-38 was minimally inhibited by 10 
µM E3S (p > 0.05), but was almost completely blocked in the presence of 100 µM RIF 
(Fig. 4B). The differential inhibition of the two OATP clones by E3S is consistent with 
the effects observed in pitavastatin uptake (14). Thus, 10 µM E3S is sufficient to inhibit 
OATP1B1, while 100 µM RIF is sufficient to inhibit both OATP1B1 and OATP1B3. 
Inhibition of OATP1B1- or OATP1B3-mediated SN-38 Uptake by Organic Anion 
Uremic Toxins.  
Since no information has been reported on the inhibitory potency of uremic 
toxins towards SN-38 transport mediated by OATP1B1 or OATP1B3, we examined the 
23 
 
effects of uremic toxin mixtures on OATP1B1- or OATP1B3-mediated uptake of SN-38. 
Both Mix1 and Mix2 significantly inhibited OATP1B1-mediated SN-38 uptake (Fig. 
4A). The mixtures also significantly inhibited OATP1B3-mediated SN-38 uptake (Fig. 
4B). Since clearance for the SN-38 uptake by OATP1B1 was higher than that by 
OATP1B3 (Fig. 3), we next examined the effect of each uremic toxin, CMPF, Indox, 
HA and IA on OATP1B1-mediated SN-38 uptake. CMPF, Indox and HA each inhibited 
OATP1B1-mediated uptake of both SN-38 and [3H]E3S in a concentration-dependent 
manner (Fig. 5A, 5B, 5C), whereas IA was less inhibitory. CMPF showed the lowest 
IC50 value among the four uremic toxins (Table 1).  
CMPF, Indox and HA showed greater inhibitory effects on 
OATP1B1-mediated uptake of SN-38 than on that of [3H]E3S (Fig. 5A, 5B, 5C). The 
IC50 values of CMPF and Indox for SN-38 uptake were lower than those for [
3H]E3S 
uptake (Table 1). The inhibition profile of CMPF for SN-38 uptake was gradual, 
compared with those of the other uremic toxins, and it was also more gradual than the 
inhibition profile of CMPF for [3H]E3S uptake (Fig. 5A). The inhibitions were 
examined within the uremic toxin concentrations where these chemicals could be 
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dissolved in the incubation mixture.  
To further characterize the inhibition by CMPF, uptake of SN-38 was 
examined at various concentrations of both SN-38 and CMPF. The Lineweaver-Burk 
plots exhibited mixed-type inhibition (Fig. 6). Thus, the inhibitory effect of CMPF is 
substrate-dependent and shows unusual kinetics, especially for SN-38 uptake. 
Inhibition by CMPF of Hepatic SN-38 Uptake. 
CMPF was demonstrated to relatively strongly inhibit OATP1B1-mediated 
uptake of SN-38 comparing to other uremic toxins (Fig. 5). Thus, the inhibition by 
CMPF of hepatic uptake of SN-38 and [3H]E3S was examined in human hepatocytes. 
Both of SN-38 and [3H]E3S uptakes were significantly inhibited by CMPF at higher 
concentrations than 100 and 30 µM, respectively (Fig. 7A, 7B). The reduction was at 
most ~40% in the higher concentration range of CMPF (Fig. 7A, 7B).  
Down-regulation of Gene Expression for OATP1B1 and OATP1B3 in the Presence 
of Uremic Plasma. 
  Finally, we examined the possible suppression of hepatic OATP1B1 and 
OATP1B3 mRNA expressions in patients with severe renal failure. For this purpose, 
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plateable human hepatocytes were incubated for 48 hr with 10% normal human plasma 
or uremic human plasma. The mRNA levels of OATP1B1, OATP1B3 and ABCB1 
observed in hepatocytes treated with normal or uremic plasma are shown in figure 8A, 
8B, 8C, respectively. Then, we combined the respective 3 data to compare the average 
mRNA levels of the transporters between hepatocytes incubated with normal and 
uremic plasma. The mRNA levels of OATP1B1 and OATP1B3 in hepatocytes treated 
with uremic plasma were much lower than those with normal plasma, whereas the 
mRNA level of ABCB1 was not different (Fig. 8D).  
 
DISCUSSION 
It seems paradoxical that plasma SN-38 concentration is elevated in patients 
with severe renal failure (6), given that SN-38 is mainly eliminated in the liver. In 
patients with severe renal dysfunction, plasma concentrations of various uremic toxins 
are elevated. In our patients with end-stage renal failure, concentrations of CMPF, Indox 
and HA were 81.1, 90.3 and 80.5 µM, respectively (6). While another report described 
the maximal plasma concentrations of 400 µM for CMPF, 940 µM for Indox and 2.6 
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mM for HA (13). SN-38 in the systemic circulation is taken up into hepatocytes, 
followed by metabolism or excretion into the bile. Therefore, we first hypothesized that, 
if a transporter(s) is involved in the uptake of SN-38 into hepatocytes, the elevated level 
of uremic toxins in plasma of the patients might inhibit the uptake process of SN-38 to 
increase the plasma concentration. Our present results first demonstrated that SN-38 
was taken up into cryopreserved human hepatocytes (Fig. 1). We next showed that the 
uremic toxin mixtures did indeed significantly, but partially, inhibit the hepatic uptake 
of SN-38 (Fig. 2A, 2B). SN-38 uptake was found to be significantly inhibited by CMPF 
in a concentration range of 100-300 µM (Fig. 7A). These results indicate that the 
hepatic uptake of SN-38 is inhibited by these uremic toxins at clinically relevant 
concentrations. Thus, the paradoxical findings in our previous clinical study might be at 
least in part explained by the direct inhibition of hepatic SN-38 uptake by uremic toxins, 
which are elevated in plasma of the end-stage patients. This is the first report to show 
uremic toxins to inhibit SN-38 uptake in human hepatocytes.  
We examined the contribution of OATPs to overall uptake of SN-38 in human 
hepatocytes by using two OATP inhibitors, E3S and RIF, since E3S can inhibit 
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OATP1B1, but RIF can inhibit both OATP1B1 and OATP1B3 when appropriate 
concentrations of E3S and RIF are used (9, 14). It was confirmed that 10 µM E3S is 
sufficient to inhibit OATP1B1-mediated uptake of SN-38, while 100 µM RIF is 
sufficient to inhibit both OATP1B1- and OATP1B3-mediated uptake (Fig. 4A, 4B). The 
fact that the SN-38 uptake in human hepatocytes was significantly inhibited by 10 µM 
E3S or 100 µM RIF (Fig. 2A, 2B) indicates a larger contribution of OATP1B1 to 
hepatic SN-38 uptake, as compared with OATP1B3. Kinetic analyses revealed that the 
uptake of SN-38 by OATP1B1 was the highest, followed by OATP1B3, and the uptake 
by OATP2B1 was negligible (Fig. 3). Therefore, OATP1B1 may be a major contributor 
to the hepatic uptake of SN-38 in humans. However, there could be limitation of using 
transporter selective inhibitors to assess relative contribution of the hepatic transporter, 
and E3S could be also the inhibitor for other transporters than OATP1B1 and OATP1B3. 
Exact contribution of these transporters should be estimated by further analyses. 
Then, another hypothesis for the elevated SN-38 concentration in patients 
with end-stage renal failure that gene expressions of SLCO1B1 and SLCO1B3 might be 
down-regulated in such patients came to us. As expected, we first demonstrated that the 
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mRNA levels of OATP1B1 and OATP1B3 in hepatocytes treated with uremic plasma 
were significantly lower than those in hepatocytes incubated with normal plasma (Fig. 
8), although the detailed mechanism(s) of the reduced gene expression at present 
remains unclear. Further studies are warranted to elucidate the mechanism(s). We are 
now investigating the effects of uremic toxins on the SLCO1B1 and SLCO1B3 gene 
expressions. Taking these results into account, the direct inhibition by uremic toxins of 
hepatic SN-38 uptake mediated by OATP1B1, together with the down-regulation of 
SLCO1B1 gene expression might partly contribute to the delayed SN-38 elimination 
observed in patients with severe renal dysfunction. Nevertheless, SN-38 has both 
lactone and carboxylate forms, which may display different transporter properties and 
show inter-conversion during the experiment. Although the present study was 
performed at the neutral pH condition which mimics human plasma, more quantitative 
analysis should be performed at the same inter-conversion condition between the uptake 
study and human plasma. Further studies are necessary to wholly understand the 
mechanisms of the phenomena.   
Considering the reports by us (6) and de Jong et al. (16), the increase in 
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plasma SN-38 concentration was only observed in patients with severe renal failure 
having creatinine clearance (CLcr) less than 20 mL/min. A similar phenomenon has 
been reported for rosuvastatin, an HMG-CoA reductase inhibitor, that is predominantly 
taken up into liver by OATP1B1 (17). The area under the concentration-time curve of 
rosuvastatin elevated only in patients with severe renal failure having CLcr less than 30 
mL/min (18). These results might suggest an analogy in mechanism(s) for elevated 
pharmacokinetic profiles of medicines that are predominantly taken up by OATP1B1 
into the liver.  
In our previous study, the plasma concentration profile of SN-38, but not 
irinotecan or SN-38 glucuronide, was significantly delayed in patients with severe renal 
failure who underwent hemodialysis, as compared with those with normal kidney (6). If 
activity or expression of carboxylesterase is altered by the patient’s renal function, 
plasma concentration profiles of irinotecan and SN-38 should be simultaneously altered. 
Similarly, pharmacokinetics of SN-38 and SN-38 glucuronide should be simultaneously 
altered when UGT1A1 activity or expression was changed. Accordingly, we at present 
rule out the possibility of the alteration of drug-metabolizing enzyme activity(s) in 
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patients with severe renal failure comparing to that in patients with normal renal 
function. However, SN-38 is excreted into bile by transporters such as MRP2 and 
BCRP, which are expressed in canalicular membranes (1, 2). Since uremic toxins have 
been shown to inhibit BCRP (19), the inhibition of SN-38 efflux transport by uremic 
toxins might complicate the interpretation of the mechanism for the change of SN-38 
elimination in patients with severe renal failure. 
Inhibition of OATP1B1 by uremic toxins exhibited two characteristic features. 
First, the inhibition exhibits substrate-dependence, the inhibitory effect being greater for 
uptake of SN-38 than for uptake of E3S (Fig. 5). Indeed, the IC50 of SN-38 for 
inhibition of OATP1B1-mediated E3S uptake was 21.0 µM, which was different from 
the Km for SN-38 uptake (~5 µM) (Fig. 3D). Similar substrate-dependent inhibition has 
been proposed in other cases, and can be accounted for by the presence of multiple 
binding sites at the catalytic site in OATP1B1 (20, 21). The present finding implies that 
uremic toxins may potently inhibit the uptake of other certain OATP1B1 substrates than 
SN-38. Since the plasma concentrations of these uremic toxins are elevated during 
severe renal failure, their interaction with other OATP1B1 substrate drugs may alter the 
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pharmacokinetics of such drugs during renal failure, even if the substrates are mainly 
eliminated in the liver. The other interesting feature of OATP1B1 inhibition by uremic 
toxins is its sigmoidal profile (Fig. 5); in particular, the inhibition by CMPF at 3 ~ 30 
µM showed a relatively gentle slope (Fig. 5A). A similar inhibition profile by CMPF 
was also found for SN-38 uptake in human hepatocytes (Fig. 7A). This atypical 
inhibition profile may also be explained by the presence of multiple binding sites on the 
transporter molecule, and leads to difficulty in identification of the type of inhibition 
from Lineweaver–Burk plots (Fig. 6). The inhibition of rat renal uptake transporters 
OAT1 and OAT3 by CMPF, Indox, HA and IA showed simple Michaelis-Menten type 
kinetics (22). Therefore, this sigmoidal profile could be a specific feature of OATP1B1. 
Further study will be needed to examine the mechanism for the substrate-dependence 
and the sigmoidal character of the inhibition by CMPF. 
The SN-38 uptake observed in HEK293/OATP1B1 or HEK293/OATP1B3 
cells (Fig. 3A, 3B) seemed to be relatively lower than that observed in human 
hepatocytes (Fig. 1A), given that the uptake studies were conducted up to 5 and 120 min 
for hepatocytes and HEK293 cell, respectively. Although the exact reason for such 
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discrepancy is unknown, it should be noted that the uptake of [3H]E3S is also higher in 
hepatocytes (Fig. 1B) than HEK293/OATP1B1 cells (see Results). In addition, we 
observed non-saturable portion of SN-38 uptake in human hepatocytes (Fig. 1C, 1D). 
Therefore, unknown transport or intracellular sequestration mechanisms that were not 
mediated by OATPs might contribute to the SN-38 uptake observed in human 
hepatocytes. 
Given that OATP1B1 predominantly mediates hepatic uptake of SN-38, 
genetic polymorphisms in SLCO1B1 that causes decreased function might greatly affect 
the pharmacokinetics of SN-38. In fact, SLCO1B1*15, which causes reduced transport 
activity (23), is reported to influence the area under the plasma concentration-time curve 
of SN-38 and irinotecan-induced toxicity (24, 25). Further studies are warranted to 
examine the effects of genetic polymorphisms in SLCO1B1 on the pharmacokinetics of 
as well as toxicity of irinotecan.  
In conclusion, we have shown for the first time that uremic toxins, CMPF, 
Indox, HA and IA inhibit SN-38 uptake in human hepatocytes at clinically relevant 
concentrations. Our results indicate that OATP1B1 is a major contributor to the 
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saturable uptake of SN-38 in human hepatocytes. The gene expression of SLCO1B1 was 
down-regulated by uremic plasma. The inhibition by uremic toxins of 
OATP1B1-mediated SN-38 uptake and the down-regulated SLCO1B1 gene expressions 
may be part of the mechanisms causing the delay of SN-38 elimination observed in 
patients with severe renal dysfunction. 
 
ACKNOWLEDGEMENT 
This study was supported in part by a Grant-in-Aid for Cancer Research from 
the Ministry of Health, Labour and Welfare of Japan [23-A-16], in part by Grant-in-Aid 
for Scientific Research (B) [24390040] and (C) [23590198] from Japan Society for the 
Promotion of Science (JSPS), in part by a Grant-in-Aid for “Support Project of Strategic 
Research Centers in Private Universities” from the Ministry of Education, Culture, 
Sports, Science and Technology (MEXT) to Saitama Medical University Research 
Center for Genomic Medicine and in part by Research Grant from National Institute of 
Biomedical Innovation.  





1. Chu XY, Kato Y, Sugiyama Y. Multiplicity of biliary excretion mechanisms for 
irinotecan, CPT-11, and its metabolites in rats. Cancer Res. 
1997;57(10):1934-1938. 
2. Chu XY, Kato Y, Ueda K, Suzuki H, Niinuma K, Tyson CA, Weizer V, Dabbs JE, 
Froehlich R, Green CE, Sugiyama Y. Biliary excretion mechanism of CPT-11 
and its metabolites in humans: involvement of primary active transporters. 
Cancer Res. 1998;58(22):5137-5143. 
3. Nakatomi K, Yoshikawa M, Oka M, Ikegami Y, Hayasaka S, Sano K, Shiozawa 
K, Kawabata S, Soda H, Ishikawa T, Tanabe S, Kohno S. Transport of 
7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein 
ABCG2 in human lung cancer cells. Biochem Biophys Res Commun. 
2001;288(4):827-832. 
4. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. Role of organic anion 
transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active 
metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of 
35 
 
single nucleotide polymorphisms. Drug Metab Dispos. 2005;33(3):434-439. 
5. Yamaguchi H, Kobayashi M, Okada M, Takeuchi T, Unno M, Abe T, Goto J, 
Hishinuma T, Mano N. Rapid screening of antineoplastic candidates for the 
human organic anion transporter OATP1B3 substrates using fluorescent probes. 
Cancer Lett. 2008;260(1-2):163-169. 
6. Fujita K, Sunakawa Y, Miwa K, Akiyama Y, Sugiyama M, Kawara K, Ishida H, 
Yamashita K, Mizuno K, Saji S, Ichikawa W, Yamamoto W, Nagashima F, Miya 
T, Narabayashi M, Ando Y, Hirose T, Sasaki Y. Delayed elimination of SN-38 in 
cancer patients with severe renal failure. Drug Metab Dispos. 
2011;39(2):161-164. 
7. Kehrer DF, Yamamoto W, Verweij J, de Jonge MJ, de Bruijn P, Sparreboom A. 
Factors involved in prolongation of the terminal disposition phase of SN-38: 
clinical and experimental studies. Clin Cancer Res. 2000;6(9):3451-3458. 
8. Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of 




9. Reyes M, Benet LZ. Effects of uremic toxins on transport and metabolism of 
different biopharmaceutics drug disposition classification system xenobiotics. J 
Pharm Sci. 2011;100(9):3831-3842. 
10. Sugiura T, Kato S, Shimizu T, Wakayama T, Nakamichi N, Kubo Y, Iwata D, 
Suzuki K, Soga T, Asano M, Iseki S, Tamai I, Tsuji A, Kato Y. Functional 
expression of carnitine/organic cation transporter OCTN1/SLC22A4 in mouse 
small intestine and liver. Drug Metab Dispos. 2010;38(10):1665-1672. 
11. Araki K, Fujita K, Ando Y, Nagashima F, Yamamoto W, Endo H, Miya T, 
Kodama K, Narabayashi M, Sasaki Y. Pharmacogenetic impact of 
polymorphisms in the coding region of the UGT1A1 gene on SN-38 
glucuronidation in Japanese patients with cancer. Cancer Sci. 
2006;97(11):1255-1259. 
12. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis 
program (multi) for microcomputer. J Pharmacobiodyn. 1981;4(11):879-885. 
13. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark 
W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, 
37 
 
Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, 
Stenvinkel P, Tetta C, Wanner C, Zidek W, European Uremic Toxin Work G. 
Review on uremic toxins: classification, concentration, and interindividual 
variability. Kidney Int. 2003;63(5):1934-1943. 
14. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 
(OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in 
humans. J Pharmacol Exp Ther. 2004;311(1):139-146. 
15. De Bruyn T, Ye ZW, Peeters A, Sahi J, Baes M, Augustijns PF, Annaert PP. 
Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities 
in individual and pooled batches of cryopreserved human hepatocytes. Eur J 
Pharm Sci. 2011;43(4):297-307. 
16. de Jong FA, van der Bol JM, Mathijssen RH, van Gelder T, Wiemer EA, 
Sparreboom A, Verweij J. Renal function as a predictor of irinotecan-induced 
neutropenia. Clin Pharmacol Ther. 2008;84(2):254-262. 
17. Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple 




18. Huang SM, Temple R, Xiao S, Zhang L, Lesko LJ. When to conduct a renal 
impairment study during drug development: US Food and Drug Administration 
perspective. Clin Pharmacol Ther. 2009;86(5):475-479. 
19. Mutsaers HA, van den Heuvel LP, Ringens LH, Dankers AC, Russel FG, 
Wetzels JF, Hoenderop JG, Masereeuw R. Uremic toxins inhibit transport by 
breast cancer resistance protein and multidrug resistance protein 4 at clinically 
relevant concentrations. PLoS One. 2011;6(4):e18438. 
20. Noe J, Portmann R, Brun ME, Funk C. Substrate-dependent drug-drug 
interactions between gemfibrozil, fluvastatin and other organic 
anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and 
OATP1B3. Drug Metab Dispos. 2007;35(8):1308-1314. 
21. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A. Functional 
characterization of human organic anion transporting polypeptide B (OATP-B) 
in comparison with liver-specific OATP-C. Pharm Res. 2001;18(9):1262-1269. 
22. Deguchi T, Kusuhara H, Takadate A, Endou H, Otagiri M, Sugiyama Y. 
39 
 
Characterization of uremic toxin transport by organic anion transporters in the 
kidney. Kidney Int. 2004;65(1):162-174. 
23. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional 
characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 
and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and 
HEK293 cells. Pharmacogenet Genomics. 2005;15(7):513-522. 
24. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Kim HT, Lee JS. 
Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) 
polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients 
with advanced non-small cell lung cancer. Lung Cancer. 2008;59(1):69-75. 
25. Takane H, Kawamoto K, Sasaki T, Moriki K, Kitano H, Higuchi S, Otsubo K, 
Ieiri I. Life-threatening toxicities in a patient with UGT1A1*6/*28 and 
SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy. Cancer 





Table 1.  Inhibition potency of uremic toxins for OATP1B1-mediated uptake of SN-38 
and [3H]E3Sa) 
---------------------------------------------------------------------------------------------------------- 
  Substrate         SN-38b)      [3H]E3Sc) 
---------------------------------------------------------------------------------------------------------- 
  CMPF (µM)    158            >300   
  Indox (µM)    2,290         4,750   
  HA (µM)    6,710        >3,000   
  IA (µM)               >3,000      >3,000   
--------------------------------------------------------------------------------------------------------- 
Inhibition potencies of the respective uremic toxins were expressed as IC50 (µM). 
a) OATP1B1-mediated uptake was measured by subtracting the uptake in 
HEK293/mock cells from that in HEK293/OATP1B1 cells. 
b) OATP1B1-mediated uptake of SN-38 for 80 min was measured. 
c) OATP1B1-mediated uptake of [3H]E3S for 3 min was measured. 
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LEGENDS TO FIGURES 
Figure 1  
Uptake of SN-38 or [3H]E3S in Human Hepatocytes 
Uptake of SN-38 (0.03 µM) and [3H]E3S (1.6 nM) by Lot#706 (●, ○) and Lot#694 
(▲ , △ ) of cryopreserved human hepatocytes is shown in panels (A) and (B), 
respectively. Panels (C) and (D) show Eadie-Hofstee plots for the uptake of SN-38 by 
Lot#706 (●) and Lot#694 (▲) of human hepatocytes, respectively. Incubations were 
performed for 5 min. Each uptake value was obtained by subtracting that of [14C]inulin, 
as an extracellular marker, and represents the mean ± SEM (n = 3). 
 
Figure 2 
Inhibition by Mixture of Uremic Toxins and OATP Inhibitors of SN-38 Uptake in 
Human Hepatocytes 
Panels (A) and (B) show the uptake of SN-38 (0.03 µM) by Lot#706 (A) and Lot#694 
(B) of cryopreserved human hepatocytes, respectively, in the presence of mixture of 
uremic toxins and OATP inhibitors, E3S and RIF. The concentrations of CMPF, Indox, 
HA and IA were 100, 100, 100 and 10 µM for Mix1 and 300, 1,000, 3,000 and 100 µM 
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for Mix2. The incubation period was 5 min. Panel (C) shows the uptake of [3H]E3S (1.6 
nM) and the inhibition by OATP inhibitors in human hepatocytes (#694) (positive 
control study). The incubation was performed for 2 min. Each uptake value was 
obtained by subtracting that of [14C]inulin, as an extracellular marker, and represents the 
mean ± SEM (n = 3-9). *, Significantly different from the control (p < 0.05). 
 
Figure 3  
Uptake of SN-38 by OATP1B1, OATP1B3 and OATP2B1 
Symbol (■) shows the uptake of SN-38 (0.03 µM) by HEK293/OATP1B1 (A), 
HEK293/OATP1B3 (B), and HEK293/OATP2B1 cells (C). The uptake of SN-38 by 
HEK293/mock cells ( □ ) was also measured. OATP1B1-, OATP1B3-, and 
OATP2B1-mediated uptake (● ) were calculated by subtracting the uptake by 
HEK293/mock cells from that by HEK293/OATP1B1, HEK293/OATP1B3, and 
HEK293/OATP2B1 cells, respectively. OATP1B1-mediated (D) and 
OATP1B3-mediated (E) uptakes of SN-38 for 80 min were measured at various SN-38 
concentrations (0.03-30 µM). Each point represents the mean ± standard error of the 
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mean (SEM) (n = 3-6). When error bars are not shown, they are smaller than symbols. 
 
Figure 4 
Inhibition by Mixture of Uremic Toxins and OATP Inhibitors of OATP1B1- and 
OATP1B3-mediated SN-38 Uptake 
Panels (A) and (B) show respective OATP1B1- and OATP1B3-mediated SN-38 (0.03 
µM) uptakes, measured in the presence of mixture of uremic toxins or each OATP 
inhibitors at the indicated concentrations. OATP1B1- and OATP1B3-mediated uptake 
was calculated by subtracting the uptake by HEK293/mock cells from that by 
HEK293/OATP1B1 and HEK293/OATP1B3 cells, respectively. The concentrations of 
CMPF, Indox, HA and IA were 100, 100, 100 and 10 µM for Mix1 and 300, 1,000, 
3,000 and 100 µM for Mix2. Incubation period was 80 min. Each value represents the 
mean ± SEM (n = 3-15). 
 
Figure 5 




Uptake of SN-38 (0.03 µM, ●) or [3H]E3S (1.6 nM, ○) by HEK293/OATP1B1 or 
HEK293/mock cells was measured in the presence of various concentrations of CMPF 
(A), Indox (B), and HA (C). OATP1B1-mediated uptake was then calculated by 
subtracting the uptake by HEK293/mock cells from that by HEK293/OATP1B1 cells. 
Each value represents the mean ± SEM (n = 3-4). Uptake period was 80 min. 
 
Figure 6 
Characterization of the Inhibition by CMPF of OATP1B1-mediated SN-38 Uptake 
Uptake of SN-38 (0.03-0.3 µM) by HEK293/OATP1B1 or HEK293/mock cells was 
measured in the presence of various concentrations of CMPF (0–300 µM). Incubation 
period was 80 min. OATP1B1-mediated uptake was then calculated by subtracting the 
uptake by HEK293/mock cells from that by HEK293/OATP1B1 cells. Data were 






Inhibitory Effect of CMPF on SN-38 and [3H]E3S Uptake by Human Hepatocytes 
Panel (A) and (B) show the uptake of SN-38 or [3H]E3S by Lot#706 (●) and Lot#694 
(▲) of human hepatocytes, respectively, in the presence of various concentration of 
CMPF. Incubations periods for SN-38 and [3H]E3S were 5 and 2 min, respectively. 
Each uptake value was obtained by subtracting that of [14C]inulin, as an extracellular 
marker, and represents the mean ± SEM (n = 3-6).  
 
Figure 8 
The mRNA Levels of OATP1B1, OATP1B3 and ABCB1 in Plateable Human 
Hepatocytes Incubated with Normal or Uremic Human Plasma  
Plateable human hepatocytes were incubated for 48 hr with each of 10% human normal 
plasma obtained from 3 patients (N1, N2 and N3) or uremic plasma from 3 patients (R1, 
R2 and R3). eGFR values in N1, N2 and N3 were 89.9, 97.5 and 66.9 mL/min, 
respectively, and those in R1, R2 and R3 were 7.0, 10.8 and 11.1 mL/min, respectively. 
The mRNA levels of OATP1B1 (A), OATP1B3 (B) and ABCB1 (C) were then 
quantified by RT-PCR. These mRNA levels were normalized by that of 36B4. The copy 
numbers in human hepatocytes incubated with 10% normal plasma were arbitrarily 
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defined as 100%. Data represents the mean ± SEM (n = 3-4). The up- and 
down-regulations of OATP1B1 mRNA by respective addition of phenobarbital and 
colhichine were confirmed as positive and negative controls 
(http://tools.invitrogen.com/content/sfs/brochures/ISSX2009InductionofTransporterExp
ressionandModulationofHepatobiliaryDisposition.pdf). Panel (D) represents the average 
of mRNA levels for respective transporters seen in panels (A-C). Data represents the 
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N1   N2   N3          R1   R2   R3 N1   N2   N3          R1   R2   R3
N1   N2   N3          R1   R2   R3
Normal Renal Failure Normal Renal Failure
Normal Renal Failure
